Long‐term use of dienogest for the treatment of primary and secondary dysmenorrhea

Yutaka Osuga, Osuga Y, Hayashi K, Kôichi Hayashi, Koichi Hayashi, Shingo Kanda, Kanda S
Journal of Obstetrics and Gynaecology Research · 2020 · vol. 46(4) , pp. 606–617 · doi:10.1111/jog.14209 · PMID:32050307 · W3005586701
article OA: bronze CC0 ⤵ 25 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-28 ⓘ

Long-term treatment with dienogest for 52 weeks effectively reduced dysmenorrhea pain and demonstrated favorable tolerability despite frequent irregular uterine bleeding.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIM: To investigate the safety and efficacy of dienogest (DNG), a progestational 19-norsteroid, administered for 52 weeks in patients with primary and secondary dysmenorrhea. METHODS: A total of 147 patients with dysmenorrhea received 1 mg of DNG orally each day for 52 weeks. The dose could be increased to 2 mg/day at or after Week 12 according to the investigator's determination. The primary safety endpoint was evaluation of adverse events, and the secondary safety endpoint was evaluation of adverse drug reactions. The number of days and severity of genital bleeding were assessed according to records in the patients' diary. Lower abdominal pain and/or low back pain because of dysmenorrhea were assessed according to the dysmenorrhea score. RESULTS: The most frequent adverse drug reaction was irregular uterine bleeding (94.6%). Most subjects completed the 52-week administration. Genital bleeding was more likely to occur in subjects with secondary dysmenorrhea than in those with primary dysmenorrhea, and in subjects with "uterine myoma or adenomyosis" than in those with "endometriosis alone." In any of the categorizations, there tended to be fewer days with genital bleeding as the treatment period increased in length, and most of the genital bleeding cases were mild. The change from baseline in the dysmenorrhea score (mean ± standard deviation [SD]) was -3.7 ± 1.6 at Week 24 of treatment and -4.0 ± 1.3 at Week 52. CONCLUSION: This study showed favorable tolerability of the long-term use of DNG to patients with dysmenorrhea and a sustainable pain relief effect.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosisadenomyosis

MeSH descriptors

Dysmenorrhea Hormone Antagonists Nandrolone Adult Drug Administration Schedule Dysmenorrhea Female Hormone Antagonists Hormone Antagonists Humans Menstruation Disturbances Menstruation Disturbances Nandrolone Nandrolone Nandrolone Severity of Illness Index Time Factors Treatment Outcome Uterine Hemorrhage Uterine Hemorrhage

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (26)

Source provenance

europepmc
last seen: 2026-08-20T06:14:21.026120+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:22:17.025735+00:00
License: CC0 · commercial use OK